Does length of prostate biopsy cores have an impact on diagnosis of prostate cancer?

Ergün, Müslüm; İslamoğlu, Ekrem; Yalcinkaya, Soner; Tokgöz, Hüsnü; Savaş, Murat

doi:10.5152/tud.2016.78700

Cited by 9 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Achieving adequate core length is crucial for the diagnosis of cancer. In two recent retrospective studies of over 2000 biopsies each, the average biopsy length was between 11.3 and 13.3 mm [11,12]. In a study of over 17,000 biopsies the average length was 10.44 ± 2.36 mm [13].…”

Section: Discussionmentioning

confidence: 99%

Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial

Forsvall

Fisher

Wagenius

et al. 2021

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Background: Transrectal prostate biopsy (TRbx) carries an increasing risk of infection. The Forsvall Needle Prototype (FNP) is a novel biopsy needle that reduces bacterial load brought across the rectum and may therefore reduce infection risk. The objective of this study was to compare biopsy length, quality and patient experience for the FNP Version 2 (FNP2) versus a standard Tru-Cut needle. Methods: We conducted a randomized, parallel-group, non-inferiority trial with twenty consecutive patients eligible for TRbx. Participants were randomized to undergo TRbx using either FNP2 or a standard Tru-Cut needle. The primary outcome was difference in mean biopsy lengths measured by the pathologist. FNP2 biopsy lengths 1.35 mm of the standard needle length were considered noninferior. Secondary outcomes were biopsy length in the needle chamber and immediately after removal, biopsy quality, biopsy fragmentation, patient discomfort/pain, and complications (immediate and after 14 and 30 days). Results: Mean pathologist-measured FNP2 biopsy length was non-inferior compared to the standard Tru-Cut needle (0.02 mm longer, 95%CI-0.73 to 0.76 mm). Biopsy length in the needle chamber and immediately after removal were also non-inferior. Biopsy quality and patient discomfort were not significantly different for the FNP2 and the standard Tru-Cut needle. Biopsy fragmentation was more common in the FNP2 group. Conclusions: The FNP2 biopsy needle is non-inferior to the Tru-Cut needle in terms of biopsy length and not significantly different in terms of biopsy quality and patient experience. Future studies will evaluate the Forsvall needle design's effect on post-biopsy infection risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial

Forsvall

Fisher

Wagenius

et al. 2021

Scandinavian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Finally, since the biopsy core length determines the quality of a specimen and given the impact of core length on cancer detection [ 25 ], we considered only the biopsy samples with a suitable length (i.e., 12 mm) and observed that our ratios worked regardless of the length of biopsy specimen, being the only predictors of Gleason score agreement.…”

Section: Discussionmentioning

confidence: 99%

“…Exclusion criteria included patients with a history of neoadjuvant hormonal therapy or chemoradiotherapy before RP surgery, active surveillance, previous surgery for benign prostatic hyperplasia (BPH), a core length less than 12 mm [ 25 ] and those patients who had incomplete medical records. Clinical and pathological data were recorded for all patients and bx-GSs were compared with their surgical counterparts.…”

Section: Methodsmentioning

confidence: 99%

Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy

et al. 2020

View full text Add to dashboard Cite

Biopsy proven Gleason score is essential to decide treatment modalities for prostate cancer, either surgical (radical prostatectomy) or non-surgical (active surveillance, watchful waiting, radiation therapy and hormone therapy). Several studies indicated that biopsy proven Gleason score may underestimate Gleason score at radical prostatectomy, hence we aimed to calculate the minimum length of biopsy cores needed to have Gleason score agreement. We evaluated 115 prostate cancer patients who underwent multiparametric magnetic resonance/transperineal ultrasonography fusion biopsy and subsequently, radical prostatectomy. Biopsy proven Gleason score was consistent with Gleason score at subsequent radical prostatectomy in 82.6% of patients, while in 17.4% of patients, Gleason score was higher at radical prostatectomy. Gleason score agreement showed a strong direct association with a ratio > 0.05 between the total volume of biopsies performed in tumor area and the volume of the corresponding tumor at radical prostatectomy. A significant association was also found with a ratio ≥ 0.0034 between the tumor volume in the biopsy and the volume of the corresponding tumor at radical prostatectomy and with a ratio ≥ 0.086 between the tumor volume in the biopsy and the total volume of biopsies performed in the tumor area. These results could be exploited to calculate the minimum length of biopsy cores needed to have a correct Gleason score estimation and therefore be used in fusion targeted biopsies with volume adjustments.

show abstract

“…Although many studies have been published on the number and localization of the cores in the literature, very few have investigated the effect of core length as an indicator of the quality of prostate biopsy (13). This may be affected by many factors, including the length of the core obtained in a biopsy, the biopsy technique performed by the urologist, the diameter of the biopsy needle, the rigidity of the site the sample obtained, and the method of sample collection (14).…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Core Lenght in Saturation Prostate Biopsy

Yücel¹,

Budak²

2018

jus

View full text Add to dashboard Cite

Objective: To investigate the effect of core length on cancer detection in saturation prostate biopsy. We hypothesized that increasing mean and total core length in saturation prostate biopsy may allow more tissue sampling, thus, may increase the prostate cancer detection rate. Materials and Methods: We retrospectively analyzed medical records of 145 patients who underwent 24-core transrectal ultrasound-guided saturation biopsy at our institution. We evaluated the clinopathological factors, including age, prostate specific antigen (PSA), prostate volume, mean core length and the total biopsy core length. The patients were divided into 3 groups according to their total biopsy core length; group 1: <20 cm, group 2: 20-30 cm and group 3: >30 cm. These groups were compared according to age, PSA value, prostate volume and cancer detection rate. Results: The mean age, core length and total core length were 62.4±7.0 years, 10.91±1.8 mm, and 26.2±4.7 cm, respectively. The overall cancer detection rate was 33.8%. There was no statistically significant difference in mean core length and total core length between patients diagnosed with prostate cancer and those without it. The cancer detection rates in group 1, 2 and 3 were 25%, 37.4% and 23.1%, respectively. When these 3 groups were compared with each other, group 2 had a statistically significantly higher cancer detection rate relative to group 1 (p=0.001). Multivariate analysis showed no statistically difference in cancer detection rate between the groups (p=0.302). Conclusion: Mean and total core length may not have any significant effect on prostate cancer detection in patients undergoing saturation prostate biopsy.

show abstract

Does length of prostate biopsy cores have an impact on diagnosis of prostate cancer?

Cited by 9 publications

References 12 publications

Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial

Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial

Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy

Clinical Value of Core Lenght in Saturation Prostate Biopsy

Contact Info

Product

Resources

About